key: cord-343677-0buclszd
authors: Roussel, Yanis; Raoult, Didier
title: Hydroxychloroquine recommendations toward the world: first evaluations
date: 2020-09-22
journal: New Microbes New Infect
DOI: 10.1016/j.nmni.2020.100759
sha: 
doc_id: 343677
cord_uid: 0buclszd

nan

Author list: Yanis ROUSSEL 1,2 , Didier RAOULT 1 Today, now that the epidemic is in a phase of decline in most of the hardest hit countries in terms of 25 mortality (5), we can issue initial assessments of the treatment strategies adopted in the world 26 according to the mortality of each of the country. We therefore determined which countries 27 recommended hydroxychloroquine using the recommendations issued by the authorities of these 28 countries and the data collected by the website c19study.com as source (Figure 1a ). Following this 29 work, we established a second map classifying the countries depending on how they were affected 30 by the epidemic (in number of deaths per million inhabitants), using the data gathered by the 31 website worldometers.info (Figure 1b) . 32 A comparison of these two maps shows that developing countries have massively turned to the use 33 of hydroxychloroquine, as well as Asian countries which present low mortality by SARS-COV2, despite 34 the fact that they have been the first to be affected by the epidemic. These countries have in 35 common the early adoption of treatments based on hydroxychloroquine and chloroquine, whether 36 or not combined with other antivirals. The countries having expressed the concerns for its use are 37 combining up to three antivirals (6). This therefore shows a discrepancy between the strategies of 40 the Western world and those of developing countries and the Far East, some being much more 41 cautious than others with regard to the use of treatments to fight against the epidemic. The opposite 42 distribution of chloroquine recommendation and fatality rate is striking and may be investigated 43 more deeply. 

Remdesivir and chloroquine effectively inhibit the recently 47 emerged novel coronavirus (2019-nCoV) in vitro

Breakthrough: chloroquine phosphate has shown apparent efficacy in 51 treatment of COVID-19 associated pneumonia in clinical studies

Hydroxychloroquine and azithromycin as a treatment of 55 COVID-19: results of an open-label non-randomized clinical trial

Maps and Trends : New Cases of COVID19 in World Countries

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus 66 disease-19 (COVID-19)